Services

FTI Consulting understands that to help meet client challenges and opportunities successfully in a global economy, you must have a full arsenal of capabilities and experience available at a moment’s notice.

M&A, Antitrust & Competition

Our economics team brings unique insights and advanced analytics from extensive experience on M&A transactions and competition issues across healthcare, life sciences and other industries.

Health Economics and Outcomes Research & Market Access

Innovative therapies offer the promise of dramatically improving patient health outcomes.

Policy & Regulation

The pace of change in healthcare is unlike any other industry.

Disputes

Clients engage our antitrust, healthcare, and industrial organization expert economist teams to provide economic testimony and privileged consulting.

Community & Economic Impact

Economic prosperity and health are linked in communities: improved health enhances economic conditions and resiliency.

Strategic & Transformational Modeling

FTI Consulting’s Center for Healthcare Economics and Policy applies cutting-edge economics and quantitative methods to assist clients.

Insights

Response to the Draft Report of the Health Economics Methods Advisory (HEMA): “Defining Appropriate Benefits for Economic Evaluation of Health Care Technologies”

Report

Patient Preferences for Attributes of Bispecific Antibodies for Relapse/Refractory Diffuse Large B-cell Lymphoma in the US

Article

Jason Shafrin Interviewed in ‘Patti’s People’ Episode on Improving Healthcare Outcomes

In the news

Imaging Utilization and Treatment Patterns of Brain Metastases in Patients With Non-Small Cell Lung Cancer: A SEER-Medicare and SEER Database Analysis

Report

Caregiver Risk Preferences for Delaying Loss of Ambulation in Duchenne Muscular Dystrophy in the United States

Article

Perspectives from the Healthcare Economist: CMS Doesn’t Consider QALYs – What’s a Health Economist To Do?

Article

A Structured Approach for Identifying Disease Analogs for Pulmonary Arterial Hypertension

Article

Perspectives from the Healthcare Economist: Why CMS/AHIP’s Prior Authorization Changes Won’t Hurt Payers

Article

Cost-Effectiveness Analysis Model for Sotagliflozin Compared with Insulin Monotherapy for Patients with Type 1 Diabetes and Chronic Kidney Disease

Article